Skip to content

The efficacy of respiratory rehabilitation for COPD-related sarcopenia: a randomized controlled trial

The efficacy of respiratory rehabilitation for COPD-related sarcopenia: a randomized controlled trial - Respiratory rehabilitation for COPD-related sarcopenia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049202
Enrollment
160
Registered
2022-10-13
Start date
2022-10-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD-related sarcopenia patients

Interventions

In addition to nutritional therapy and psychotherapy, conditioning is performed on an outpatient basis once a week for 40 minutes. (Three months rehabilitation period) In addition to nutritional ther

Sponsors

Nippon Sport Science University
Lead Sponsor
Department of respiratory medicine at 1. Kanto central hospital 2. National Hospital Organization Tokyo Medical Center 3. Teikyo University Hospital, Mizonokuchi 4. Tamagawa Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. COPD patients aged more than 40 years old 2. had 10-pack years of smoking history 3. diagnosed as sarcopenia using AWGS 2019 guideline

Exclusion criteria

Exclusion criteria: 1. history of respiratory rehabilitation within one year. 2. history of acute exacerbation within one month. 3. patients using oxygen therapy. 4. patients receiving chemotherapy. 5. Severe diabetes mellitus (retinopathy, fundus hemorrhage, during dialysis, the complication of peripheral neuropathy) 6. Severe heart disease (acute myocardial infarction, pacemaker wearer, unstable angina, uncontrolled heart failure, advanced obstructive hypertrophic cardiomyopathy, acute embolism, acute infectious diseases (pericarditis, myocarditis)

Design outcomes

Primary

MeasureTime frame
The total walking distance by shuttle walking (Compare after 3-month rehabilitation)

Secondary

MeasureTime frame
1. Improvements in sarcopenia indicators such as SMI and grip strength, quadriceps maximum voluntary contraction, 4-m gait speed, and 5-repetition sit-to-stand test. (Compare after 3-month rehabilitation) 2. respiratory muscle strength (Pimax, Pemax) (Compare after 3-month rehabilitation) 3. Questionnaire such as CAT, kihon check list (Compare after 3-month rehabilitation) 4. Eat-10 questionnaire (Compare after 3-month rehabilitation) 5. measurement of tongue pressure (Compare after 3-month rehabilitation) 6. MMSE and HADS Questionnaire (Compare after 3-month rehabilitation) 7. J-CHS assessment (Compare after 3-month rehabilitation) 8. Physical activity measured by a 3-axis accelerometer(step counts, METS/day, Time in LPA, MPA and VPA) (Compare after 3-month rehabilitation) 9. Measurements done three months and six months after rehabilitation will also be compared. 10. Highly sensitive Elisa measurement of sarcopenia-related proteins in urinary exosomes (parkin, Activin RIIA, Myostatin). These results will be reported separately. 11. Walking analysis (stride, Pronation, impact on landing, etc.) These results will be reported separately.

Countries

Japan

Contacts

Public ContactMitsuo Hashimoto

Nippon Sport Science University Faculty of Sport Science, Department of Health Science

mitsuo-hashimoto@nittai.ac.jp81-3-5706-0862

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026